DDInter1212 DDInter1652
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Midazolam {u} (Compound) resembles {v} (Compound) Fludiazepam
Midazolam {u} (Compound) resembles {v} (Compound) Camazepam
Midazolam {u} (Compound) treats {v} (Disease) epilepsy syndrome
Midazolam {u} (Compound) binds {v} (Gene) CYP3A4
Midazolam {u} (Compound) is included by {v} (Pharmacologic Class) Benzodiazepines
Midazolam {u} (Compound) downregulates {v} (Gene) TUBB6
Midazolam {u} (Compound) causes {v} (Side Effect) Nystagmus
Midazolam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prednisone
Midazolam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Midazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimethobenzamide
Midazolam (Compound) resembles Fludiazepam (Compound)
Midazolam (Compound) resembles Camazepam (Compound)
Midazolam (Compound) treats epilepsy syndrome (Disease)
Midazolam (Compound) binds CYP3A4 (Gene)
Midazolam (Compound) is included by Benzodiazepines (Pharmacologic Class)
Midazolam (Compound) downregulates TUBB6 (Gene)
Midazolam (Compound) causes Nystagmus (Side Effect)
Midazolam may cause a minor interaction that can limit clinical effects when taken with Prednisone
Midazolam may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide